---
document_datetime: 2026-01-28 12:41:43
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/genvoya-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: genvoya-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.1498239
conversion_datetime: 2026-02-01 20:44:14.587447
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.1
  docling: 2.71.0
  docling-core: 2.62.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Genvoya

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type II /  | This was an application for a group of | 15/01/2026                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000308403   |
|---------------------|

<div style=\"page-break-after: always\"></div>

|                                       | A grouped application consisting of three Type II variations, as follows: C.I.11 for RMP: Submission of an updated RMP version 6.1 in order to propose the removal of the Important Identified Risk of 'Suicidal ideation/suicide attempt in patients with a preexisting history of depression or psychiatric illness C.I.11 for RMP: Submission of an updated RMP version 6.1 in order to propose the removal of the Important Identified Risk of 'Concurrent use of drugs whose coadministration with Genvoya is contraindicated'. C.I.11 for RMP: Submission of an updated RMP version 6.1 in order to propose the removal of the following Missing Information: 'Safety in   |            |     |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000284417 | A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted                                                                                                                                                        | 02/09/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                            | manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted   |                                                                                                                                                                                                                                                                                                         |
|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUR / EMA/PSUR/0000248490 | - -                                                                                                                                                                                                                          | Based on the PRAC review of data on safety and efficacy, the PRAC considers that the risk-benefit balance of medicinal products containing cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide remains unchanged and therefore recommends the maintenance of the marketing authorisation. |